Skip to content

Effect of Huangqijishengtang on deficiency of liver and kidney in rheumatoid arthritis and its effect on bone metabolism

Effect of Huangqijishengtang on deficiency of liver and kidney in rheumatoid arthritis and its effect on bone metabolism

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042329
Enrollment
Unknown
Registered
2021-01-19
Start date
2021-01-19
Completion date
Unknown
Last updated
2021-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

Sponsors

The Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Meet the 2010 ACR/EULAR diagnostic criteria for RA; (2) It conforms to the diagnostic criteria of WP liver and kidney deficiency syndrome; (3) It met the diagnostic criteria of osteopenia based on DXA measurement results; (4) Age between 18 and 70, gender is not limited; (5) DAS28 score < 5.1; (6) Volunteered to take the test and signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) Severe joint deformity, the classification of the activities and functions of III level or above; (2) Have taken drugs affecting bone metabolism within 3 months, such as glucocorticoids, cyclosporine A, bisphosphonates, antiepileptic drugs, tumor chemotherapies, thyrosteroids, estrogen progesterone, etc.; (3) Suffer from other diseases that may be secondary to osteoporosis, such as: endocrine diseases (Cushing syndrome, hyperthyroidism, type I diabetes), hematologic diseases (leukemia, systemic mastocytosis, etc.), chronic renal failure, etc.; (4) Patients with primary osteoporosis; (5) Complicated with other rheumatic immune diseases, or heart, liver, kidney and other important viscera diseases, or complicated with various acute or chronic infections or other infectious diseases; (6) Have a history of contraindications and allergies to experimental drugs; (7) Have a history of alcohol abuse, drug abuse or neuropsychiatric disorders (epilepsy, depression, etc.); (8) Pregnant or lactating women who have a recent birth plan; (9) Participating in clinical studies of other drugs.

Design outcomes

Primary

MeasureTime frame
Therapeutic Effect of TCM Diseases;TCM syndrome score;DAS28 score;Hip bone mineral density measured by DXA;

Secondary

MeasureTime frame
Joint swelling number;Number of joint tenderness;Morning stiffness time;HAQ;Improved Sharp Score;11/5000 ACR20 compliance rate;VAS score for the degree of pain assessed by the patient;The patient assessed the overall condition of the disease VAS score;The overall condition VAS score for the disease was assessed by the researchers;ESR;CRP;Blood electrolyte;measurement of T lymphocyte subsets;RF parting;CCP;OPG;PINP;ALP;D-MID;ß-CTX;cytokines;

Countries

China

Contacts

Public ContactXiaohu Tang

Yunnan Traditional Chinese Medicine Hospital

a1014920218@icloud.com+86 18648467038

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026